Virax Biolabs Group Ltd (NASDAQ:VRAX) does about 4.36M shares in volume on a normal day but saw 14771029 shares change hands in the recent trading day. The company now has a market cap of 12.33M USD. Its current market price is $2.84, marking an increase of 9.65% compared to the previous close of $2.59. The 52 week high reached by this stock is $9.00 whilst the lowest price level in 52 weeks is $0.60.
Virax Biolabs Group Ltd (VRAX) has a 20-day trading average at $4.16 and the current price is -68.44% off the 52-week high compared with 373.33% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.40 and its 200-day simple moving average is $1.40. If we look at the stock’s price movements over the week, volatility stands at 15.95%, which increases to 31.25% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 46.21 to suggest the stock is neutral.
The consensus objective for the share price is $20.00, suggesting that the stock has a potential upside of 85.8% over the period.
The current price level is -31.08%, 19.88%, and 102.69% away from its SMA20, SMA50, and SMA200 respectively, with the VRAX price moving below the 50-day SMA on current market day. Virax Biolabs Group Ltd (VRAX) stock is down -10.97% over the week and 104.32% over the past month. Its price is 94.52% year-to-date and -24.79% over the past year.
To reach the target analysts have set, the stock logically needs to grow 85.8 percent from here.
Outstanding shares total 4.34M with insiders holding 7.07% of the shares and institutional holders owning 1.75% of the company’s common stock. The company has a return on investment of -121.48% and return on equity of -92.92%. The beta has a value of 2.19. Price to book ratio is 1.36 and price to sales ratio is 77.03.
